Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Bessesen, D
Neuroimaging , vol
A retrospective study conducted at the University Health Network found that, in liver transplant recipients with diabetes, combination therapy reduced HbA1c and alanine aminotransferase levels more effectively than DPP-4 inhibitors. Additionally, two clinical trials in patients with Type 2 diabetes demonstrated that combination therapy significantly lowered HbA1c by 1.34% and 1.21%, compared to a 0.54% reduction with placebo, starting from a baseline of 8.0%. These findings suggest that combination therapy may be especially beneficial in the liver transplant population, where patients often experience weight gain and develop metabolic co-morbidities
Phase I Safety Profile: While topical and low-dose injectable formulations demonstrate high tolerance and minimal systemic toxicity, there is no formal Phase I safety data for chronic 85 mg/day intranasal delivery in humans
Deficiency of mitophagy receptor FUNDC1 impairs mitochondrial quality and aggravates dietary-induced obesity and metabolic syndrome
US$ 28.72
US$ 27.70
US$ 22.50
